CUE - Cue Biopharma - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CUE is currently covered by 5 analysts with an average price target of $6.82. This is a potential upside of $6.04 (774.36%) from yesterday's end of day stock price of $0.78.

Cue Biopharma's activity chart (see below) currently has 14 price targets and 21 ratings on display. The stock rating distribution of CUE is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 12.38% with an average time for these price targets to be met of 24.33 days.

Highest price target for CUE is $4, Lowest price target is $2, average price target is $4.6.

Most recent stock forecast was given by MAURY RAYCROFT from JEFFERIES on 15-Nov-2024. First documented stock forecast 24-Feb-2020.

Currently out of the existing stock ratings of CUE, 11 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$4

$2.9 (263.64%)

$6

5 months 24 days ago
(15-Nov-2024)

0/2 (0%)

$2.75 (220.00%)

Buy

$4

$2.9 (263.64%)

$8

8 months 19 days ago
(20-Aug-2024)

1/5 (20%)

$3.14 (365.12%)

12

Buy

$2

$0.9 (81.82%)

$15

9 months 13 days ago
(26-Jul-2024)

2/5 (40%)

$1.33 (198.51%)

60

Buy

$3

$1.9 (172.73%)

$8

9 months 13 days ago
(26-Jul-2024)

0/3 (0%)

$2.33 (347.76%)

Buy

$10

$8.9 (809.09%)

$10

1 years 10 months 13 days ago
(26-Jun-2023)

1/7 (14.29%)

$6.29 (169.54%)

74

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CUE (Cue Biopharma) average time for price targets to be met?

On average it took 24.33 days on average for the stock forecasts to be realized with a an average price target met ratio 12.38

Which analyst has the current highest performing score on CUE (Cue Biopharma) with a proven track record?

RENI BENJAMIN

Which analyst has the current lower performing score on CUE (Cue Biopharma) with a proven track record?

MAURY RAYCROFT

Which analyst has the most public recommendations on CUE (Cue Biopharma)?

Reni Benjamin works at JMP and has 24 price targets and 18 ratings on CUE

Which analyst is the currently most bullish on CUE (Cue Biopharma)?

Reuben Garner with highest potential upside - $23.89

Which analyst is the currently most reserved on CUE (Cue Biopharma)?

Reni Benjamin with lowest potential downside - $0.9

Cue Biopharma in the News

Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know

The market expects Cue Biopharma, Inc. (CUE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company’s earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?